ALTERATION OF FLUOROURACIL METABOLISM IN HUMAN-COLON CANCER-CELLS BY DIPYRIDAMOLE WITH A SELECTIVE INCREASE IN FLUORODEOXYURIDINE MONOPHOSPHATE LEVELS
- 1 December 1986
- journal article
- research article
- Vol. 46 (12) , 6191-6199
Abstract
The nucleoside transport inhibitor dipyridamole can increase the cytotoxicity of 5-fluorouracil in a human colon cancer cell line (HCT 116) without affecting the total amount of fluorouracil incorporated into the acid soluble and insoluble fractions (J. L. Grem and P. H. Fischer, Cancer Res., 45: 2967-2972, 1985). We now report that dipyridamole altered the pattern of fluorouracil metabolism and provided a selective increase in intracellular fluorodeoxyuridine monophosphate (FdUMP) levels. At 2 and 4 h after exposure to fluorouracil and dipyridamole, FdUMP levels were approximately 5-fold higher in the presence of dipyridamole. The ratio of FdUMP to fluorouridine triphosphate at 4 h was substantially increased in the presence of dipyridamole (0.4 .+-. 0.05) compared to fluorouracil alone (0.08 .+-. 0.03). In cells preloaded with fluorodeoxyuridie (FdUrd), dipyridamole potently inhibited the efflux of FdUrd, leading to an increased retention of intracellular FdUMP. One h following removal of [6-3H]FdUrd, the FdUMP levels were increased 8-fold in the presence of dipyridamole, and the half-life of intracellular FdUMP was increased from 24 to 78 min. We have previously shown that the addition of sufficient thymidine (25 .mu.M) can prevent the augmentation of fluorouracil toxicity produced by dipyridamole. In these studies, the addition of 25 .mu.M thymidine reduced the FdUMP levels to less than half of these measured in the presence of fluorouracil plus dipyridamole for the first 8 h of exposure, and reduced the FdUMP levels to 6% of the FdUMP levels seen with fluorouracil and dipyridamole after 24 h of exposure. Thymidine prevented the enhanced intracellular retention of FdUMP produced by dipyridamole in cells preloaded with FdUrd. In addition, thymidine inhibited the accumulation of FdUMP in cells exposed to FdUrd. In cancer cells which significantly catabolize FdUMP, the ability of dipyridamole to block the reflux of FdUrd may provide an effective means of selectively increasing FdUMP levels and enhancing the toxicity of fluorouracil. Furthermore, dipyridamole blocked the efflux of deoxyuridine and prolonged the intracellular half-life of deoxyuridine monophosphate. In cells prelabeled with [2''-3H]dUrd, transfer of tritium to FdUrd and FdUMP occurred in cells exposed to fluorouracil and dipyridamole. These data suggest that blockade of nucleoside efflux can enhance the availability of deoxyribose-1-phosphate donors for the synthesis of FdUrd. Thus, dipyridamole''s ability to inhibit nucleoside transport can perturb the metabolism of a nucleobase, fluorouracil.This publication has 21 references indexed in Scilit:
- Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation.Proceedings of the National Academy of Sciences, 1980
- Methotrexate-induced misincorporation of uracil into DNAProceedings of the National Academy of Sciences, 1980
- MECHANISMS OF SENSITIVITY AND RESISTANCE OF MURINE TUMORS TO 5-FLUOROURACIL1980
- ASSESSMENT OF GROWTH-LIMITING EVENTS CAUSED BY 5-FLUOROURACIL IN MOUSE CELLS AND IN HUMAN-CELLS1980
- In Vivo Potentiation of 5-Fluorouracil Cytotoxicity Against AKR Leukemia by Purines, Pyrimidines, and Their Nucleosides and Deoxynucleosides2JNCI Journal of the National Cancer Institute, 1980
- MECHANISM FOR EXCLUSION OF 5-FLUOROURACIL FROM DNA1980
- Biochemical determinants of tumor sensitivity to 5-fluorouracil: Ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetaseProceedings of the National Academy of Sciences, 1979
- SELECTIVE-INHIBITION OF PYRIMIDINE SYNTHESIS AND DEPLETION OF NUCLEOTIDE POOLS BY N-(PHOSPHONACETYL)-L-ASPARTATE1979
- Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil responseBiochemical Pharmacology, 1978
- Cancer Treatment Today and Its Impact on Drug Development, With Special Emphasis on the Phase II Clinical TrialJNCI Journal of the National Cancer Institute, 1976